Ceritinib Rare Indications Study in ALK+ Tumors

NCT02465528 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Tumors With Aberrations in ALK
Anaplastic Large Cell Lymphoma
Inflammatory Myofibroblastic Tumor
Glioblastoma

Interventions

DRUG: Ceritinib (LDK378)

Sponsor

Novartis Pharmaceuticals